Pfizer Axes 3 Drugs From Pipeline in Q1 2017 Business, Cognitive Disorders, Glucagon Receptor Antagonist, Guidance, Hyperlipidemia, Product Pipelines, Quarterly results, Type 1 Diabetes In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects. Read more May 2, 2017/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2017-05-02 05:24:182017-05-02 13:37:13Pfizer Axes 3 Drugs From Pipeline in Q1 2017
